Evidence map›Paper›PMID 42509551›Full record

ArticleBMC medical genomics2026

Benchmarking sequence-based and AlphaFold-based methods for pMHC-II binding core prediction: distinct strengths and consensus approaches.

Soobon Ko, Honglan Li, Hongeun Kim, Woong-Hee Shin, Junsu Ko, Yoonjoo Choi

Abstract read
In one paragraph

Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. AlphaFold3: An Overview of Applications and Performance Insights.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Soobon KoDepartment of Microbiology and Immunology, Chonnam National University Medical School, Hwasun, Jeollanam-Do, 58128, Republic of Korea.
Honglan LiArontier Inc., Seoul, 06735, Republic of Korea.
Hongeun KimArontier Inc., Seoul, 06735, Republic of Korea.
Woong-Hee ShinDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, 02841, Republic of Korea.
Junsu KoArontier Inc., Seoul, 06735, Republic of Korea.
Yoonjoo ChoiDepartment of Microbiology and Immunology, Chonnam National University Medical School, Hwasun, Jeollanam-Do, 58128, Republic of Korea. kalicuta@gmail.com.ORCID 0000-0001-9687-8093

Funding

Institute for Information and Communications Technology Promotion IITP-2024-RS-2022-00156439Institute for Information and Communications Technology Promotion IITP-2024-RS-2024-00438263Korea Health Industry Development Institute NRF-2024M3A9J4006525Ministry of Health and Welfare RS-2025-25459531Ministry of Science and ICT, South Korea NRF-2020M3A9G3080281Ministry of Science and ICT, South Korea NRF-2020R1A5A2031185Ministry of Science and ICT, South Korea RS-2024-00462620Ministry of Science and ICT, South Korea RS-2025-02213506
6 · The paper itself

Abstract

backgroundInteractions between peptide and MHC class II (pMHC-II) are crucial for T-cell recognition and immune responses, as MHC-II molecules present peptide fragments to T cells, enabling the distinction between self and non-self antigens. Accurately predicting the pMHC-II binding core is particularly important because it provides insights into pMHC-II interactions and T-cell receptor engagement. Given the high polymorphism and peptide-binding promiscuity of MHC-II molecules, computational prediction methods are essential for understanding pMHC-II interactions. While sequence-based methods are widely used, recent advances in AlphaFold-based structure prediction have opened new possibilities for improving pMHC-II binding core predictions.

methodsWe constructed a non-redundant dataset of 72 pMHC-II complexes from the IMGT database, supplemented with shuffled negative peptides and curated non-binders. Two sequence-based methods (NetMHCIIpan-4.3 and DeepMHCII) and two structure-based methods (AlphaFold2 fine-tuned (AF-FT) and AlphaFold3 (AF3)) were benchmarked for binding and core prediction. Performance was evaluated using standard metrics (precision, recall, F1 score), and consensus strategies integrating sequence- and structure-based models were developed for scenarios with known and unknown binding status.

resultsThe AlphaFold-based methods showed strong performance in predicting positive binders, with AF3 achieving the highest positive recall (0.86) and AF2-FT performing similarly (0.81). However, both methods frequently misclassified unbound peptides as binders. NetMHCIIpan excelled at identifying non-binders, achieving the highest negative recall (0.93), but had lower positive recall (0.44). In contrast, DeepMHCII demonstrated moderate performance without any notable strength. Consensus approaches combining AlphaFold-based methods for binder identification with filtering using NetMHCIIpan improved overall prediction precision (0.94 and 0.87 for known and unknown binding status, respectively).

conclusionsThis study highlights the complementary strengths of AlphaFold-based and sequence-based methods for predicting pMHC-II binding core regions. AlphaFold-based methods excel in predicting positive binders, while NetMHCIIpan is highly effective at identifying non-binders. Future research should focus on improving the prediction of unbound peptides for AlphaFold-based models. Since NetMHCIIpan's binding core predictive ability is already high, future efforts should concentrate on enhancing its binding prediction to further improve overall accuracy.

Indexed as

Computational BiologyHistocompatibility Antigens Class IIPeptidesAmino Acid SequenceBenchmarkingBinding SitesHumansPrediction AlgorithmsProtein BindingHistocompatibility Antigens Class IIPeptidesAlphaFoldBinding coreConsensusPeptide bindingpMHC-II

Identifiers

PMID42509551
PMCPMC13410576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.